Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Oral Peptide Formulations (Semaglutide and NNC0385-0434)
NCT05129891Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2021
- Primary completion
- Feb 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial in type 2 diabetes mellitus (T2DM) and hypercholesterolemia comparing Part A: Oral semaglutide with Part B: NNC0385-0434 (2 arms). Primary endpoint: Area under the API plasma concentration-time curve from 0 to 24 hours. Started Nov 2021; status: completed.
02
Drugs
semaglutideNNC0385-0434
03
Conditions
type 2 diabetes mellitus (T2DM)hypercholesterolemia
Beyond the preview
Go deeper on NCT05129891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05129891.